DRKS00013271已完成未知
Medication safety in patients treated with new oral anticancer agents: a prospective randomized investigation on the impact of intensified clinical pharmaceutical/clinical pharmacological care on patient safety and patient reported outcome - AMBORA
Apotheke des Universitätsklinikums Erlangen; Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie der FAU Erlangen-Nürnberg0 个研究点目标入组 202 人开始时间: 2017年11月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 202
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Initiation of therapy with an oral anticancer agent, cancer diagnosis, adult patient, planned duration of therapy / estimated lifespan of at least 4 months, ability to complete questionnaires
排除标准
- •Prolonged inpatient stay and concomitant i.v. chemotherapy with classical cytostatic drugs, lack of german language skills, cognitive impairment, non-consenting patients, patients who are not able to take their medicine on their own, pregnant / lactating women, missing written consent
研究者
相似试验
已完成
不适用
Effectiveness and safety of oral and intralesional tranexamic acid in treatment of melasmaCTRI/2021/08/035350Department of Dermatology42
尚未招募
3 期
Study to compare the effectiveness and safety of two drugs in atopic dermatitis in childreCTRI/2024/02/063274IMS and SUM Hospital
招募中
2 期
The effect of an inhibitor of pulmonary inflammation in patients with Covid-19RBR-5s2mqgFaculdade de Ciências Médicas da Universidade Estadual de Campinas
已完成
Unknown
Safety evaluatioJPRN-UMIN000048716EP Mediate Co., Ltd10
进行中（未招募）
1 期
A post-marketing safety study in patients with moderate renal insufficiency who receive Omniscan (Gadodiamide Injection) for contrast enhanced magnetic resonance imaging (MRI)Estudio de seguridad poscomercialización en pacientes con insuficiencia renal moderada a los que se les administra OMNISCAN (inyección de gadodiamida) para la adquisición de imágenes de RM (IRM) realzada con contraste.Patients with moderate renal insufficiency (estimated eGFR > 30 and <60 mL/min/1.73m2).Pacientes con insuficiencia renal moderada (tasa de filtración glomerular [TFG] >estimada 30 y <60 ml/min/1,73 m2).MedDRA version: 9.1Level: LLTClassification code 10064499Term: Nephrogenic fibrosing dermopathyEUCTR2009-011236-35-ESGE Healthcare Limited and its Affiliates600